SpectRx makes progress with cervical cancer device:
This article was originally published in Clinica
SpectRx says it has built and tested its first pre-production noninvasive cervical cancer detection device, which is to be used to complete the firm's ongoing US clinical trial necessary for regulatory approval. The beta device and single-patient-use disposables comprise major components planned for use in commercial production. The Norcross, Georgia company believes that the new-generation system will enable it to reach its price-of-production goals, making the technology affordable to physicians. The device, which uses proprietary technology to identify cancers and precancers painlessly by analysing light reflected from the cervix, is to be commercialised by SpectRx' subsidiary, Guided Therapeutics. SpectRx estimates the annual global market potential for a noninvasive cervical cancer test to be over $1.3bn.